New review guides first and second line therapy choices for moderate-to-severe Crohn’s disease

A new meta-analysis has given fresh insights into the optimal sequence of first- and second-line therapies in moderate-to-severe Crohn’s disease, gastroenterologists say. The systematic review and network meta-analysis included 31 clinical trials of  TNF inhibitors (infliximab, adalimumab, and certolizumab pegol), anti-integrins (vedolizumab), anti-IL-12/23p40 agents (ustekinumab), and anti-IL-23p19 agents (risankizumab). The latest evaluation found infliximab alone ...

Already a member?

Login to keep reading.

© 2021 the limbic